At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma
In Brief
A Phase 1 clinical trial evaluating Placebo and Tezepelumab for Asthma. Completed, enrolled 31 participants across 5 sites.
Detailed Summary
The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartOct 2011
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 29, 2011
Enrollment StartOct 31, 2011
Primary CompletionApr 5, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.9 years ago
Interventions
Placebodrug
Administered in a 1-hour intravenous infusion
Tezepelumabbiological
Administered in a 1-hour intravenous infusion